1h Free Analyst Time
The epidermal growth factor receptor (EGFR) inhibitors market is forecasted to grow by USD 6.75 bn during 2023-2028, accelerating at a CAGR of 8.6% during the forecast period. The report on the epidermal growth factor receptor (EGFR) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rise in the prevalence of major cancer indications, increasing awareness and adoption of personalized medicine, and advancements in technology and research.
The epidermal growth factor receptor (EGFR) inhibitors market is segmented as below:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
By Indication
- Lung cancer
- Colorectal cancer
- Breast cancer
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the epidermal growth factor receptor (EGFR) inhibitors market covers the following areas:
- Epidermal growth factor receptor (EGFR) inhibitors market sizing
- Epidermal growth factor receptor (EGFR) inhibitors market forecast
- Epidermal growth factor receptor (EGFR) inhibitors market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Indication
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global epidermal growth factor receptor (EGFR) inhibitors market: Amgen Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Hansoh Pharmaceutical Group Co. Ltd., hutchison medipharma ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Puma Biotechnology Inc., Takeda Pharmaceutical Co. Ltd., Apollomics Inc., CULLINAN ONCOLOGY INC., and Lutris Pharma.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increase in research areas for treatment of various types of cancer.'
According to the report, one of the major drivers for this market is the rise in the prevalence of major cancer indications.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- ASSERTIO HOLDINGS INC.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Checkpoint Therapeutics Inc.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Hansoh Pharmaceutical Group Co. Ltd.
- hutchison medipharma ltd.
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Johnson and Johnson
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Puma Biotechnology Inc.
- Takeda Pharmaceutical Co. Ltd.
- Apollomics Inc.
- CULLINAN ONCOLOGY INC.
- Lutris Pharma
